Combined interferon alpha with levamisole in patients with metastatic renal cell carcinoma

被引：5

作者：

Aksoy H. ^{[1
]}

Baltaci S. ^{[2
]}

Türkölmez K. ^{[2
]}

Seçkiner I. ^{[2
]}

Bedük Y. ^{[2
]}

机构：

[1] Ümitköy girişi Melis Sitesi, Çayyolu, Ankara 06530

[2] Department of Urology, Ankara University, School of Medicine, Ankara

来源：

International Urology and Nephrology | 2001年 / 33卷 / 3期

关键词：

Toxicity; Interferon; Renal Cell Carcinoma; Partial Response; Body Surface;

D O I：

10.1023/A:1019510628249

中图分类号：

学科分类号：

摘要：

To evaluate the efficacy and toxicity of interferon alpha-2b (IFN-α2b) and levamisole treatment regimen in patients with metastatic renal cell carcinoma (RCC). Seventeen patients with metastatic RCC were treated using recombinant IFN-α2b at a dose of 10 MU/m2 body surface subcutaneously three times in a week, for 3 months, with levamisole 50 mg t.d.s orally on days 1-3 on alternate weeks. The mean follow-up period was 10.7 (range 2-23) months. We achieved 1 complete response (lasting for 12+ months) and 1 partial response (lasting for 15 months), for an objective response rate of 11.7%. A further 7 patients (41%) had a stabilization of disease. The overall toxicity was moderate, with mainly grade I or II side effects. Grade III toxicities reported among 3 patients including vomiting (2 patients) and anorexia (1 patient). There was no treatment related death. Although additions of levamisole to IFN-α do not result in any significant increase in treatment toxicity, the response rate appears to be no better than IFN-α monotherapy reported in the literature.

引用

页码：457 / 459

页数：2

共 15 条

[1]

Bukowski R.M., Natural history and therapy of metastatic renal cell carcinoma, Cancer, 80, pp. 1198-2000, (1997)

[2]

Motzer R.J., Nusso P., Systemic therapy for renal cell carcinoma, J Urol, 163, pp. 408-417, (2000)

[3]

Rosenberg S.A., Yang J.C., Topalian S.L., Et al., Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2, JAMA, 271, pp. 907-913, (1994)

[4]

Taylor J.L., Papadimitrou J., Effects of interferons on cell growth and function, Interferon: General and Applied Aspects, 1, (1984)

[5]

Wirth M.P., Immunotherapy for metastatic renal cell carcinoma, Urol Clin North Am, 20, pp. 283-295, (1993)

[6]

Ahmed F.Y., Leonard G.A., A'Hern R., Et al., A randomized dose escalation study of subcutaneous interleukin 2 with and without levamisole in patients with metastatic renal cell carcinoma or malignant melanoma, Br J Cancer, 74, pp. 1109-1113, (1996)

[7]

Redondo J.M., Lopez-Guerrero J.A., Fresno M., Potentiation of IL-2 sensitivity by levamisole and imidazole, Immunol Lett, 14, pp. 111-116, (1986)

[8]

Creagan E.T., Hestorff R.D., Suman V.J., Et al., Combined levamisole with recombinant interleukin-2 (IL-2) in patients with advanced renal cell carcinoma, Am J Clin Oncol, 21, pp. 139-141, (1998)

[9]

WHO Handbook for Reporting Results of Cancer Treatment, 48, (1979)

[10]

Motzer R.J., Bander N.H., Nanus D.M., Renal-cell carcinoma, N Engl J Med, 335, pp. 865-875, (1996)

← 1 2 →